The rapamycin reversal: why the longevity crowd is backing off

By Marcus Renshaw ·

For most of the last decade, rapamycin was the closest thing the longevity world had to a sure bet. It targets mTOR, the nutrient-sensing pathway most consistently tied to aging across species, and it was the first drug ever shown to extend lifespan in mammals. If you read longevity forums in 2022, the question was not whether to take it, but how to find a doctor who would prescribe it off label. By late 2024 the mood had turned. The human data arrived thinner than the mouse data promised, an epigenetic warning sign appeared, and the movement’s most visible self-experimenter quietly stopped. This is what actually happened, and why I took my own rapamycin plan off the table.

Rapamycin reliably extends lifespan in mice, which is why it became the longevity world’s favorite drug. In humans the evidence is much thinner. The year-long PEARL trial missed its primary endpoint, and some multi-clock epigenetic data suggests intermittent dosing may not slow biological aging and could speed a few markers. It is promising and unproven, not a default.

Why was rapamycin the longevity world’s favorite drug?

Because the animal evidence is genuinely strong, and it targets the right pathway. mTOR senses nutrients and tells cells to grow and divide; dial it down and cells shift toward repair and recycling, which is roughly what fasting and calorie restriction do. Rapamycin dials it down directly.

The landmark result came from the NIA Interventions Testing Program, which runs the same drug at three independent labs to avoid single-site flukes. Fed rapamycin starting at 20 months of age, the rough equivalent of a 60 year old human, median lifespan rose about 14% in female mice and 9% in males. That it worked when started late in life is the part that captured people. You did not have to begin in your twenties. In mice, at least, the clock could be slowed after middle age. No other drug had done this, and the pathway it hit was the one everyone already believed mattered most.

What actually happened when they tested it in humans?

The single best human trial to date, PEARL, came back mostly null on the thing it set out to measure. It followed 114 adults aged 50 to 85 for 48 weeks on placebo, 5 mg, or 10 mg of rapamycin once a week. The primary endpoint was visceral fat. It did not change significantly. Blood biomarkers stayed within normal ranges, and side effects were no worse than placebo, so the drug looked safe at those intermittent doses.

There were bright spots in the secondary results: women on 10 mg gained lean tissue and reported less pain, and the 5 mg group reported better well-being. Those are worth something. But they are secondary endpoints in a one-year study, and the headline number, the one the trial was built to move, did not move. That is a long way from “extends human lifespan.” It is the difference between a drug that is plausibly safe and modestly useful and a drug that reverses aging. The hype had been selling the second story on the strength of the first kind of evidence.

Why did Bryan Johnson stop taking it?

Bryan Johnson ran rapamycin for close to five years as part of a heavily measured regimen, then stopped in late 2024. His stated reasons are the interesting part. Two things drove it. First, ordinary side effects that accumulated: intermittent soft tissue infections, worse blood lipids, raised glucose, a higher resting heart rate, none catastrophic but none pointing the right way for a longevity drug. Second, and the reason it made news, his own biological-age tracking across multiple epigenetic clocks did not show the slowing he expected, and some signals pointed toward faster aging on the drug rather than slower.

One person’s self-tracking is not evidence, and Johnson is the first to frame it that way. But it landed because it rhymed with a broader shift. Epigenetic clocks are now being used to screen aging interventions quickly, and a large 2024 analysis harmonized 51 human interventional studies across 16 clocks to do exactly that. When the community’s fastest read on “is this working” stops confirming the favorite drug, confidence wobbles.

Does that mean rapamycin accelerates aging?

No, and this is where honesty matters more than a clean narrative. The picture is genuinely mixed. In mice, rapamycin does not just extend lifespan, it also slows epigenetic aging signatures in the liver, so the animal story is coherent: better lifespan, younger-looking methylation. The human acceleration signal comes from intermittent weekly dosing, from smaller and often preprint-level data, and from clocks that are themselves noisy (more on that in what epigenetic clocks actually measure). It is a reason to withhold confidence, not a proof of harm.

So the accurate summary is boring: strong mouse lifespan data, a coherent mouse mechanism, thin human outcome data, one null primary endpoint in the best trial, and an epigenetic warning sign that is suggestive rather than settled. That is not a scandal. It is what the early evidence for most longevity interventions looks like once you stop grading on enthusiasm.

So should you take it?

Rapamycin is a prescription immunosuppressant used off label here, so this is a decision for you and a clinician, not a blog, and it is not medical advice. If you do run it, the monitoring is the point: lipids, fasting glucose and HbA1c, and a low threshold for taking infections seriously, because those are the predictable costs the PEARL and Johnson experiences both flagged. This is the self-experimenter’s version of the guideline being a floor: the clinical caution exists for a reason, and optimizing on top of it means watching the safety markers more closely, not less.

The deeper lesson is about how you weight evidence. Rapamycin is the cautionary tale for treating a strong animal result and a validated pathway as if they were a proven human benefit. The same discipline that says most supplements should be dropped until they earn their place applies to the glamorous end of the stack too. A drug does not get a pass on the evidence bar because its mechanism is elegant.

What I am doing

I have low-dose rapamycin on my someday list, in the “add it when I find a prescriber who will manage it” column, precisely because I rate mTOR as the most validated aging pathway there is. It has never been in my regimen, gated behind a prescription I have not gone chasing, and the 2024 and 2025 reversal is why I am in no hurry to. Nothing here says rapamycin is a bad bet forever. It says the human case is not made yet, the fastest instruments we have are not confirming it, and the drug carries real metabolic and immune costs. When the trade is “unproven benefit for measurable side effects,” waiting is a position, not indecision. I would rather spend that attention on levers where the human evidence is already in.

If you are building a longevity stack, the useful move is not picking the trendiest molecule. It is setting up the measurement first, so that when you do add something you can actually tell whether it worked. A single tracked number is where that habit starts, and the free BP tracker is a zero-cost place to build it.

FAQ

Does rapamycin extend human lifespan?

There is no direct evidence that it does. The lifespan data is from mice, where rapamycin reliably extends median lifespan even when started in middle age. In humans the best trial to date, PEARL, ran for one year, measured healthspan markers rather than lifespan, and missed its primary endpoint of reduced visceral fat. Human lifespan benefit is a hypothesis, not a finding.

What did the PEARL trial actually show?

PEARL followed 114 adults aged 50 to 85 for 48 weeks on weekly rapamycin or placebo. The primary endpoint, visceral fat, did not change significantly. Some secondary measures improved, including lean tissue and pain in women on the higher dose, and the drug appeared safe at those intermittent doses. It supported safety and hinted at modest benefits, but did not demonstrate that rapamycin slows aging.

Why did Bryan Johnson stop taking rapamycin?

After close to five years, he cited accumulating side effects, including soft tissue infections, worse lipids, higher glucose, and a raised resting heart rate, plus his own biological-age tracking failing to show the slowing he expected. It is one person’s self-experiment, not a trial, but it echoed a wider loss of confidence as epigenetic clocks were increasingly used to screen aging interventions.

Does rapamycin accelerate aging?

The evidence is mixed. In mice it slows epigenetic aging markers alongside extending lifespan. The human acceleration signal comes from intermittent weekly dosing and smaller, often preprint-level data, using clocks that are noisy to begin with. It is a reason to hold off on strong claims of benefit, not proof that the drug speeds aging.

Is rapamycin safe to take for longevity?

At the low intermittent doses studied it appeared reasonably safe over a year, but it is a prescription immunosuppressant with real predictable costs: worse lipids, higher glucose, and infection risk. It requires a prescriber and ongoing monitoring. Whether the uncertain benefit justifies those costs is an individual decision to make with a clinician, not a default choice.

What is mTOR and why does it matter for aging?

mTOR is a cellular pathway that senses nutrients and drives growth and division. Turning it down shifts cells toward repair and recycling, similar to the effect of fasting or calorie restriction. It is the aging pathway with the most cross-species evidence behind it, which is exactly why rapamycin, an mTOR inhibitor, drew so much longevity interest.

Sources